Global Cord Blood (NYSE:CO) & Lisata Therapeutics (NASDAQ:LSTA) Head-To-Head Contrast

Global Cord Blood (NYSE:COGet Rating) and Lisata Therapeutics (NASDAQ:LSTAGet Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Global Cord Blood and Lisata Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Global Cord Blood 0 0 0 0 N/A
Lisata Therapeutics 0 0 2 0 3.00

Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 256.29%. Given Lisata Therapeutics’ higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Global Cord Blood.


This table compares Global Cord Blood and Lisata Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Global Cord Blood 40.29% 10.63% 6.02%
Lisata Therapeutics N/A -29.53% -27.96%

Risk & Volatility

Global Cord Blood has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Institutional & Insider Ownership

15.6% of Lisata Therapeutics shares are held by institutional investors. 2.2% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Global Cord Blood and Lisata Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood $196.12 million 1.85 $79.04 million $0.64 4.67
Lisata Therapeutics N/A N/A -$27.47 million ($12.23) -0.34

Global Cord Blood has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.


Global Cord Blood beats Lisata Therapeutics on 7 of the 12 factors compared between the two stocks.

About Global Cord Blood

(Get Rating)

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

About Lisata Therapeutics

(Get Rating)

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with's FREE daily email newsletter.